Daniel E Bauer
Overview
Explore the profile of Daniel E Bauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
9197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee J, Zeng J, Liu P, Nguyen M, Loustaunau D, Bauer D, et al.
Nucleic Acids Res
. 2024 Dec;
53(1.
PMID: 39676659
Recently, cytosine base editors (CBEs) have emerged as a promising therapeutic tool for specific editing of single nucleotide variants and disrupting specific genes associated with disease. Despite this promise, the...
2.
Zeng J, Nguyen M, Liu P, da Silva L, Levesque S, Lin L, et al.
Cell Stem Cell
. 2024 Dec;
32(2):191-208.e11.
PMID: 39672163
Gene editing the BCL11A erythroid enhancer is a validated approach to fetal hemoglobin (HbF) induction for β-hemoglobinopathy therapy, though heterogeneity in edit allele distribution and HbF response may impact its...
3.
Demirci S, Zeng J, Palchaudhuri R, Wu C, Abraham D, Hayal T, et al.
Cell Stem Cell
. 2024 Dec;
32(2):209-226.e8.
PMID: 39642886
Editing the +58 region of the BCL11A erythroid enhancer has shown promise in treating β-globin disorders. To address variations in fetal hemoglobin (HbF) response, we investigated editing both +58 and ...
4.
5.
Becerra B, Wittibschlager S, Patel Z, Kutschat A, Delano J, Che E, et al.
bioRxiv
. 2024 Sep;
PMID: 39314441
CRISPR tiling screens have advanced the identification and characterization of regulatory sequences but are limited by low resolution arising from the indirect readout of editing via guide RNA sequencing. This...
6.
Lin J, Nguyen M, Lin L, Zeng J, Verma A, Neri N, et al.
bioRxiv
. 2024 Aug;
PMID: 39211178
Genome editing with RNA-guided DNA binding factors carries risk of off-target editing at homologous sequences. Genetic variants may introduce sequence changes that increase homology to a genome editing target, thereby...
7.
Levesque S, Cosentino A, Verma A, Genovese P, Bauer D
Nat Biotechnol
. 2024 May;
PMID: 38806736
Therapeutic prime editing of hematopoietic stem and progenitor cells (HSPCs) holds great potential to remedy blood disorders. Quiescent cells have low nucleotide levels and resist retroviral infection, and it is...
8.
Yan J, Oyler-Castrillo P, Ravisankar P, Ward C, Levesque S, Jing Y, et al.
Nature
. 2024 Apr;
628(8008):639-647.
PMID: 38570691
Prime editing enables the precise modification of genomes through reverse transcription of template sequences appended to the 3' ends of CRISPR-Cas guide RNAs. To identify cellular determinants of prime editing,...
9.
Demirci S, Khan M, Hinojosa G, Le A, Leonard A, Essawi K, et al.
Cytotherapy
. 2024 Mar;
26(6):641-648.
PMID: 38506770
Ex vivo resting culture is a standard procedure following genome editing in hematopoietic stem and progenitor cells (HSPCs). However, prolonged culture may critically affect cell viability and stem cell function....
10.
Luk K, Liu P, Zeng J, Wang Y, Maitland S, Idrizi F, et al.
GEN Biotechnol
. 2024 Feb;
1(3):271-284.
PMID: 38405215
Type V CRISPR-Cas12a systems are an attractive Cas9-alternative nuclease platform for specific genome editing applications. However, previous studies demonstrate that there is a gap in overall activity between Cas12a and...